IRIS
RIMASSA, Lorenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.660
AS - Asia 8.116
EU - Europa 2.538
SA - Sud America 1.648
AF - Africa 350
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 12
AN - Antartide 2
Totale 25.350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.323
SG - Singapore 4.943
CN - Cina 1.370
BR - Brasile 1.364
VN - Vietnam 773
IT - Italia 480
FI - Finlandia 454
IE - Irlanda 334
DE - Germania 308
HK - Hong Kong 242
FR - Francia 208
NG - Nigeria 206
CA - Canada 204
IN - India 175
GB - Regno Unito 174
NL - Olanda 133
BD - Bangladesh 118
AR - Argentina 110
SE - Svezia 88
TR - Turchia 81
MX - Messico 76
IQ - Iraq 62
RU - Federazione Russa 56
JP - Giappone 52
ID - Indonesia 48
ZA - Sudafrica 44
CL - Cile 41
EC - Ecuador 41
BE - Belgio 38
IL - Israele 37
PL - Polonia 37
ES - Italia 35
AT - Austria 34
UA - Ucraina 33
CO - Colombia 32
PK - Pakistan 29
SA - Arabia Saudita 26
UZ - Uzbekistan 24
MA - Marocco 22
AU - Australia 21
VE - Venezuela 21
EG - Egitto 18
PH - Filippine 18
LT - Lituania 16
CZ - Repubblica Ceca 15
KE - Kenya 15
PY - Paraguay 15
AZ - Azerbaigian 14
DZ - Algeria 14
NP - Nepal 12
PT - Portogallo 12
UY - Uruguay 12
IR - Iran 11
AE - Emirati Arabi Uniti 10
JM - Giamaica 10
JO - Giordania 10
TN - Tunisia 10
KR - Corea 9
PE - Perù 9
BY - Bielorussia 8
CH - Svizzera 8
EU - Europa 8
KZ - Kazakistan 8
CR - Costa Rica 7
MY - Malesia 7
BG - Bulgaria 6
ET - Etiopia 6
GR - Grecia 6
HR - Croazia 6
KG - Kirghizistan 6
MD - Moldavia 6
RO - Romania 6
SV - El Salvador 6
AL - Albania 5
DO - Repubblica Dominicana 5
HN - Honduras 5
LB - Libano 5
NI - Nicaragua 5
NO - Norvegia 5
RS - Serbia 5
TT - Trinidad e Tobago 5
BA - Bosnia-Erzegovina 4
GT - Guatemala 4
HU - Ungheria 4
LV - Lettonia 4
OM - Oman 4
PA - Panama 4
TH - Thailandia 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AO - Angola 3
BB - Barbados 3
BH - Bahrain 3
KH - Cambogia 3
ML - Mali 3
PS - Palestinian Territory 3
AQ - Antartide 2
BO - Bolivia 2
GA - Gabon 2
MT - Malta 2
SK - Slovacchia (Repubblica Slovacca) 2
Totale 25.320
Salva come PNG Salva come JPEG
Città #
Singapore 2.153
Dallas 1.767
Wilmington 1.288
Chandler 1.285
Ashburn 889
The Dalles 632
San Jose 598
Shanghai 564
San Mateo 477
Helsinki 454
Ann Arbor 394
New York 363
Dublin 333
Beijing 329
Ho Chi Minh City 275
Lawrence 253
Princeton 252
Boardman 244
Leawood 232
Hong Kong 218
Benin City 205
Los Angeles 189
Hanoi 178
Santa Clara 162
Milan 150
Paris 146
Amsterdam 110
Fairfield 108
Woodbridge 108
Buffalo 106
São Paulo 103
Toronto 95
London 86
Phoenix 67
Columbus 60
Seattle 55
Council Bluffs 50
Orem 46
Montreal 43
San Diego 42
Naples 41
Rio de Janeiro 41
Kocaeli 39
Belo Horizonte 36
Brussels 35
Chicago 35
Da Nang 35
Falkenstein 35
Tokyo 35
Brasília 32
Chennai 32
Haiphong 32
Pune 32
Abbiategrasso 31
Munich 31
Redwood City 31
Warsaw 31
Mexico City 30
Assago 28
Charlotte 28
Norwalk 28
Salvador 27
Brooklyn 25
Baghdad 22
Curitiba 22
Tashkent 22
Hải Dương 20
Porto Alegre 20
Atlanta 19
Dhaka 19
Houston 19
Johannesburg 19
San Francisco 19
Campinas 18
Guayaquil 18
Frankfurt am Main 17
Manchester 17
Boston 16
Moscow 16
Pasadena 16
Guarulhos 15
Redmond 15
Baku 14
Jeddah 14
Milwaukee 14
Mumbai 14
Ninh Bình 14
Ribeirão Preto 14
St Louis 14
Andover 13
Biên Hòa 13
Jakarta 13
Monmouth Junction 13
Rome 13
Stockholm 13
Fortaleza 12
Istanbul 12
New Delhi 12
Santiago 12
Denver 11
Totale 16.443
Salva come PNG Salva come JPEG
Nome #
Prognostic Factors and Survival Outcomes in Resected Biliary Tract Cancers: A Multicenter Retrospective Analysis 311
The Lancet Commission on addressing the global hepatocellular carcinoma burden: comprehensive strategies from prevention to treatment 265
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence 186
Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report 167
An exploratory biomarker study in metastatic tumors from colorectal cancer patients treated with bevacizumab 157
18F-FDG PET and CT scan in the pre-operative evaluation of colorectal liver metastases treated with chemotherapy 157
18F-FDG pet does not improve contrast enhanced CT scan sensitivity in the evaluation of liver metastases after chemotherapy 153
Aggressive and Multidisciplinary Local Approach to Iterative Recurrences of Colorectal Liver Metastases 141
5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors 137
Alpha-fetoprotein screening in patients with hepatitis C-induced cirrhosis who achieved a sustained virologic response in the direct-acting antiviral agents era 135
Metastasis of hepatocellular carcinoma to the heart: A case report and review of the literature 128
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study 128
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer 128
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer 125
Tivantinib for hepatocellular carcinoma 120
A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients with Advanced Hepatocellular Carcinoma 118
Tivantinib for Second-line Treatment of Advanced MET-High Hepatocellular Carcinoma: A Phase 3, Randomized, Placebo-Controlled Study (METIV-HCC) 116
Tumor-associated macrophages and response to 5-flourouracil adjuvant therapy in stage III colorectal cancer 115
Tumor-derived prostaglandin E2 promotes p50 NF-κB-dependent differentiation of monocytic MDSC 112
Design, conduct, and analyses of Breast International Group (BIG) 1-98: A randomized, double-blind, phase-III study comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive, early breast cancer 111
Can SBRT improve the prognosis of unresectable pancreatic cancer? Clinical results on 106 patients 111
Biomarkers in Hepatocellular Carcinoma-Letter 110
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 109
COVID-19 and liver cancer clinical trials: not everything is lost 108
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma 107
Pharmacological inactivation of DNA repair to improve response to immunotherapy: The Arethusa trial in metastatic colorectal cancer 106
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 106
Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications 105
Biliary Tract Cancers: Molecular Heterogeneity and New Treatment Options 105
Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy 104
Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner 104
Adrenal metastases from adenocarcinoma of the esophagogastric junction: adrenalectomy and long-term survival. 103
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer 101
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 101
Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study 100
Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole 99
Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights 98
Antiangiogenic drugs currently used for colorectal cancer: What other pathways can we target to prolong responses? 98
Diagnostic accuracy of C-11-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma 98
High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models 97
Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach 96
Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. 95
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial 94
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma 94
Clinical implications of immunohistochemical assessment of somatostatin receptors subtype 2 and 5 in the diagnostic and therapeutic management of gastro-entero-pancreatic neuroendocrine tumours 94
Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma 94
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma 94
Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression 93
Prognostic value of the immune-related transcriptome in biliary tract cancers 92
Budget impact of bimonthly use of cetuximab in patients diagnosed with metastatic colorectal cancer 92
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98 92
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer 91
Cabozantinib for the treatment of hepatocellular carcinoma 90
Characterisation of the immune-related transcriptome in resected biliary tract cancers 90
The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer 90
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 90
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab 89
Irinotecan and raltitrexed: an active combination in advanced colorectal cancer 89
From barriers to solutions: an expert-based algorithm for cholangiocarcinoma and other biliary tract cancers testing in the Era of precision oncology 88
Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial 88
FOLFOX/CAPOX in stage II–III colon cancer: efficacy results of the Italian Three Or Six Colon Adjuvant trial (TOSCA) 88
Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: are we aware of the therapeutic impact of intratumor heterogeneity? 88
Long-term outcomes after pancreatoduodenectomy for ampullary cancer: The influence of the histological subtypes and comparison with the other periampullary neoplasms 88
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 87
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 86
Shaping the landscape of immune oncology in hepatocellular carcinoma 86
Cabozantinib in patients with hepatocellular carcinoma failing previous treatment with sorafenib 86
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up 86
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 86
Are we ready for patient-reported outcomes in hepatocellular carcinoma? 86
Risk of Cancer in Inflammatory Bowel Diseases: Umbrella Review and Reanalysis of Meta-analyses 85
Prognostic value of the neutrophil-to-lymphocyte ratio in hepatocellular carcinoma: an exploratory analysis from the second-line ARQ 197-215 study 85
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma 85
Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib 84
Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma 84
Reply to Y. Pointreau et al 84
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 84
Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer 84
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 84
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience. 84
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 83
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 83
Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date 83
The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine 83
Medical Oncologists must get more involved in systemic treatment of Hepatocellular Carcinoma 83
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma 83
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma 83
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study 83
Fatal Infusion Reaction to Cetuximab: The Need for Predictive Risk Factors and Safer Patient Selection 83
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 82
Chemotherapy with mitomycin c and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin 82
KRAS mutation in lung metastases from colorectal cancer : Prognostic implications 82
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications 81
Nicotinamide phosphoribosyltransferase acts as a metabolic gate for mobilization of myeloid-derived suppressor cells 81
Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers 81
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab 81
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 80
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study 79
Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-alpha in dacarbazine-resistant malignant melanoma 79
Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial 79
Totale 10.259
Salva come PNG Salva come JPEG
Categoria #
all - tutte 163.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 163.235
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021249 0 0 0 0 0 0 0 0 0 0 0 249
2021/20221.504 61 43 20 316 28 33 70 219 136 211 270 97
2022/20233.786 563 174 342 440 302 293 35 310 675 355 257 40
2023/20242.440 161 251 455 89 76 341 161 127 36 53 278 412
2024/20253.714 121 62 29 57 75 432 284 337 580 794 424 519
2025/202611.892 1.462 1.455 1.081 1.192 339 527 2.794 506 535 768 675 558
Totale 25.874